Biosimilar Newsletter Archive

  1. 06.14.18 -- How Biosimilars Can Win Over U.S. Payers
    6/14/2018
    06/14/18 Biosimilar Development Newsletter
  2. 06.07.18 -- Key Learnings Shaping Pfizer’s Biosimilar Business
    6/7/2018
    06/07/18 Biosimilar Development Newsletter
  3. 05.31.18 -- The Importance Of Pass-Through Status For Biosimilars
    5/31/2018
    05/31/18 Biosimilar Development Newsletter
  4. 05.24.18 -- Incentivizing Clinics: A Biosimilar Maker's Guide
    5/24/2018
    05/24/18 Biosimilar Development Newsletter
  5. 05.17.18 -- Pfizer Executives Share Biosimilar Goals, Challenges
    5/17/2018
    05/17/18 Biosimilar Development Newsletter
  6. 05.10.18 -- 3 Biosimilar Barriers In Community Clinics
    5/10/2018
    05/10/18 Biosimilar Development Newsletter
  7. 05.03.18 -- The Importance Of Humanizing Biosimilars
    5/3/2018
    05/03/18 Biosimilar Development Newsletter
  8. 04.26.18 -- 90 Studies Prove Biosimilars’ Safety And Efficacy: What Now?
    4/26/2018
    04/26/18 Biosimilar Development Newsletter
  9. 04.19.18 -- Does The U.S. Biosimilar Space Have A Case Of “Progressophobia?”
    4/19/2018
    04/19/18 Biosimilar Development Newsletter
  10. 04.12.18 -- Could This Practice Increase U.S. Biosimilar Use?
    4/12/2018
    04/12/18 Biosimilar Development Newsletter